IA 期混合型子宫内膜癌的预后。

The Prognosis of Stage IA Mixed Endometrial Carcinoma.

机构信息

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China.

Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China.

出版信息

Am J Clin Pathol. 2019 Oct 7;152(5):616-624. doi: 10.1093/ajcp/aqz083.

DOI:10.1093/ajcp/aqz083

PMID:31318970

Abstract

OBJECTIVES

To explore the survival and definition of stage IA mixed endometrial carcinoma.

METHODS

From June 1, 2010, to June 1, 2017, cases with stage IA endometrial cancer were included in this study. The survival outcomes were compared among patients with endometrioid (group A), nonendometrioid (group B), and mixed subtypes (group C) and among patients with different proportions of nonendometrioid components (<5%, >50%, and others).

RESULTS

In total, 890 cases were included, comprising 808 (90.8%), 33 (3.7%), and 47 (5.3%) cases in groups A, B, and C, respectively. After a median follow-up of 55.9 months, groups B and C had significantly more inferior disease-free survival, overall survival, and cancer-specific overall survival. Patients with a nonendometrioid proportion of more than 50% and serous subtype also had a significantly more inferior prognosis. Adjuvant therapy could improve the prognosis in mixed endometrial carcinomas.

CONCLUSIONS

Patients with endometrial cancer of mixed subtypes had inferior survival outcomes.

摘要

目的

探讨 IA 期混合性子宫内膜癌的生存情况和定义。

方法

本研究纳入了 2010 年 6 月 1 日至 2017 年 6 月 1 日期间的 IA 期子宫内膜癌患者。比较了子宫内膜样（A 组）、非子宫内膜样（B 组）和混合亚型（C 组）患者以及非子宫内膜样成分比例不同（<5%、>50%和其他）患者的生存结局。

结果

共纳入 890 例患者，A、B、C 组分别为 808 例（90.8%）、33 例（3.7%）和 47 例（5.3%）。中位随访 55.9 个月后，B 组和 C 组的无病生存率、总生存率和癌症特异性总生存率明显更差。非子宫内膜样成分比例>50%和浆液性亚型的患者预后也明显更差。辅助治疗可以改善混合性子宫内膜癌的预后。